Popular Searches
New Clinical Trial for Meningitis
This clinical trial explores how certain peptides called CGRP and substance P, which can change during meningitis, might help doctors diagnose and treat the disease better, bringing new hope for patients.
Clinical trials are vital for improving medical care. This report highlights the Evaluation of the Levels of Calcitonin Gene-related Peptide and Substance P trial (NCT06510751), which is studying how these peptides may be used to improve diagnosis and treatment outcomes in patients with post-operative meningitis, a serious infection that can occur after brain surgery.
Understanding new research is a top priority for patients and caregivers seeking information on treatment options, managing side effects, and exploring potential avenues for improvement. This post aims to provide a clear overview of what this trial is about and how it could potentially impact the future of Meningitis care.
Meningitis is an infection and inflammation of the protective membranes around the brain and spinal cord. It is a serious neurological illness that can develop after surgery involving brain catheters, making diagnosis challenging. Current tests may not always clearly identify the infection. Research like the Meningitis Peptide Study is important to find new ways, such as checking neuropeptides like CGRP and substance P, to identify the disease earlier and understand the treatment response better.
PubMed-indexed journal: This clinical trial measures the amounts of two molecules, CGRP and substance P, in people who have had brain surgery and developed meningitis. The goal is to see if the levels of these molecules in body fluids can help doctors better diagnose meningitis and monitor how patients respond to treatment. The study focuses on infections related to the use of tubes placed in the brain, aiming to improve early detection and outcome predictions. [1].
PubMed-indexed journal: This scientific study looks at how a molecule called substance P affects blood vessels in the brain during bacterial meningitis, using rats as a model. It shows that substance P causes blood vessels on the brain’s surface to get wider during the early stages of meningitis. This widening of blood vessels is one of the early body reactions to the infection. [2].
Meningitis can manifest in various ways, but some of the most common symptoms include:
These symptoms can make daily activities very hard for patients. Understanding and recognizing these symptoms early helps patients get the right care quickly. The Meningitis Peptide Study aims to find better ways to confirm the diagnosis and monitor how patients respond to treatment.
The Meningitis Peptide Study is observing how levels of two neuropeptides, called CGRP (calcitonin gene-related peptide) and substance P, change in patients with post-operative meningitis.
CGRP and substance P are tiny proteins called neuropeptides that nerves release, especially when there is damage or inflammation. They can affect how the body reacts to infections like meningitis. This study measures their amounts in blood and spinal fluid to see if they can help doctors diagnose meningitis or track how well treatments are working.
This study is specifically designed to assess how useful CGRP and substance P levels are in diagnosing meningitis caused by brain surgery and in predicting how patients respond to treatment.
CGRP and substance P are neuropeptides that communicate signals in the nervous system, especially during damage or infection. When meningitis occurs, these peptides may increase, influencing immune responses and pain signals. Studying their levels helps scientists understand their role in disease and whether they can serve as markers to guide treatment.
This trial is one of the few to analyze how CGRP and substance P change in patients with bacterial meningitis after surgery. By using sensitive tests to measure these peptides in blood and spinal fluid, the study hopes to find new markers that better detect meningitis and predict outcomes, potentially leading to faster, more precise care.
The study is designed as a prospective cohort observation, following patients suspected of meningitis in intensive care to see how peptide levels correlate with disease progression and treatment success. This approach helps gather real-world data without changing current treatments.
The Meningitis Peptide Study (NCT06510751) embodies this crucial role in research, offering a potential path to:
Clinical trials have specific criteria to ensure the safety of participants and the validity of the study results. For the Meningitis Peptide Study trial, key eligibility criteria include:
If you are deemed eligible and choose to enroll in the Meningitis Peptide Study, you can expect the following general process:
The duration of your participation will vary depending on the study design, but the research team will explain the full commitment before enrollment.
Like all medical interventions, participation in a clinical trial carries both potential benefits and risks.
A detailed explanation of all potential risks and benefits will be provided during the informed consent process.
The Meningitis Peptide Study (NCT06510751) is currently recruiting at Akdeniz University School of Medicine, Department of Anesthesiology and Intensive Care in Antalya, Turkey.
If you are interested in potentially participating, it is crucial to discuss these criteria with your healthcare provider. They can determine if you meet the specific requirements. You may share this link with your provider’s email address, or have them visit ClinQuestAi.com and type in NCT06510751.
You can also:
Remember: Deciding to participate in a clinical trial is a personal choice. It’s important to discuss all aspects of the trial with your healthcare provider to ensure it’s the right decision for your individual health situation.
All health-related content on this website, whether drafted by our team or with AI assistance, undergoes a rigorous human review process before publication. Every article is fact-checked, edited, and medically reviewed by a licensed medical professional with relevant expertise. Our goal is to provide information that is accurate, aligned with current medical consensus, empathetic, and useful for patients and caregivers. We are committed to transparency, clearly citing sources and displaying author and reviewer credentials to uphold the highest standards of E-E-A-T (Experience, Expertise, Authoritativeness, and Trustworthiness).